Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease was published in January this year. The authors include researchers at The Telethon Kids Institute, Perron Institute and Murdoch University.
Potential targets in chronic kidney disease (CKD) are discussed as well as problems faced by antisense drug development in this indication.
One suggested solution to the issue of toxicity is the "employment of nucleotide analogues of improved safety profile, such as PMO ...."
One of the suggested potential targets for treating CKD, APOL 1, is already being investigated by Astra Zeneca in collaboration with Ionis.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)